BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the agency was unable to inspect Hanmi Bioplant, the drug substance...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

OncoImmune raises $56M series BOncoImmune Inc. raised $56 million in a series B round co-led by HM Capital and an undisclosed investor. Also participating were fellow new investors GBA Fund and GF Xinde, and existing...
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...announced inconclusive results from its Phase Ib trial evaluating the analgesic effects of KarXT, a CHRM1/CHRM4...
...factor (SCF) receptor tyrosine kinase CHRM1 (HM1) - Muscarinic acetylcholine receptor M1 CHRM4 (HM4) - Muscarinic acetylcholine receptor M4...
BioCentury | Jul 29, 2020
Product Development

July 28 Quick Takes: Spectrum gains on NSCLC data; plus Nabriva, Farxiga, Chi-Med, Merck-Lumos, BeiGene, Aerie, jCyte and moreBy BioCentury Staff

Spectrum therapy hits Phase II endpoint Poziotinib met the prespecified primary endpoint in the ZENITH20 Phase II trial in previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations (Cohort 2),...
BioCentury | Dec 26, 2019
Clinical News

Spectrum’s value halved after poziotinib’s failure in NSCLC cohort

Eleven months after Spectrum divested its marketed products to sharpen its focus on a pair of clinical candidates, one of the two has failed in the first cohort of a Phase II trial, while the...
BioCentury | Dec 19, 2019
Financial News

Versant’s Pipeline raises $30M series B for regenerative therapies

Aiming to enter the clinic before year end, Versant-backed Pipeline Therapeutics raised $30 million in a series B led by new investor Sectoral Asset Management. Versant Ventures also participated in the round, along with new...
BioCentury | Nov 18, 2019
Clinical News

Karuna quintuples in value as schizophrenia combo clears Phase II bar

...Muscarinic acetylcholine receptor M2; CHRM3 (HM3) - Muscarinic acetylcholine receptor M3; CHRM4 (HM4) - Muscarinic acetylcholine receptor M4 Paul...
BioCentury | Nov 18, 2019

Targeting muscarinic acetylcholine receptors to treat anemia

...treat anemia associated with myelodysplastic syndrome (MDS), aging or hemolysis. In mice with MDS, a CHRM4...
...hemoglobin levels, and orphenadrine citrate extended survival. In mice with age- or hemolysis-associated anemia, the CHRM4...
...serum hematocrit and hemoglobin levels as well as red blood cell counts. TARGET/MARKER/PATHWAY: Muscarinic acetylcholine receptor M4 (CHRM4; HM4...
BioCentury | Jul 8, 2019
Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

Skyhawk, Merck in neurology, cancer deal Skyhawk Therapeutics Inc. (Waltham, Mass.) and Merck & Co. Inc. (NYSE:MRK) parterned to discover, develop and commercialize small molecules capable of modulating RNA splicing discovered using Skyhawk’s SkySTAR platform...
BioCentury | May 6, 2019
Financial News

May 6 Financial Quick Takes: Athenex, Spiral

Athenex raises $100M to advance Oraxol Looking to fund commercialization activities for Oraxol and advance its oncology pipeline and actinic keratosis therapy, Athenex Inc. (NASDAQ:ATNX) raised $100 million in a private placement through the sale...
Items per page:
1 - 10 of 262